EP1042476A1 - Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation - Google Patents

Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation

Info

Publication number
EP1042476A1
EP1042476A1 EP98965865A EP98965865A EP1042476A1 EP 1042476 A1 EP1042476 A1 EP 1042476A1 EP 98965865 A EP98965865 A EP 98965865A EP 98965865 A EP98965865 A EP 98965865A EP 1042476 A1 EP1042476 A1 EP 1042476A1
Authority
EP
European Patent Office
Prior art keywords
peptides
acid sequence
amino acid
peptide
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98965865A
Other languages
German (de)
English (en)
Inventor
Wolf-Georg Forssmann
Ludger STÄNDKER
Maik Obendorf
Lothar Kling
Hans-Georg Opitz
Hossein Mostafavi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1042476A1 publication Critical patent/EP1042476A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Insulin-like growth factor binding protein fragments and their use
  • the present invention relates to peptides with cell proliferative and cell protective properties, complexes of the peptides with human insulin-like growth factor I and II (IGF) and the associated nucleic acids, antisense nucleotides, antibodies and inhibitors.
  • IGF insulin-like growth factor I and II
  • Insulin-like growth factor binding proteins are described, inter alia, by Shimasaki, S. and Ling, N. in Prog. Growth Factor Res. 3 (1991) 243-266 and Zapf, J. in Eur. J. Endocrinol. 132 (1995) 645-654.
  • the present invention relates to peptides whose amino acid sequence corresponds in part to the amino acid sequence of insulin-like growth factor binding proteins, and to cyclic, glycosylated, phosphorylated, acetylated, acidated and / or sulfated derivatives thereof. These peptides according to the invention are referred to as IGFBP or IBP.
  • Preferred peptides are those that occur naturally and can be isolated, for example, from hemofiltrate.
  • the peptides preferably have a length of 61 to 115 amino acids.
  • Peptides which have sequences which correspond to N- or C-terminal sequences of insulin-like growth factor binding proteins are particularly preferred.
  • Preferred peptides are peptides with the amino acid sequence of the formula
  • R NH 2 , an amino acid or a peptide with an amino acid sequence comprising up to 41 amino acids
  • X a peptide with an amino acid sequence comprising 24 to 31 amino acids
  • X represents a peptide with an amino acid sequence comprising 9 amino acids
  • X 3 represents a peptide with an amino acid sequence comprising 10 amino acids
  • X 4 represents a peptide with an amino acid sequence comprising 18 to 24 amino acids
  • the peptide has cell proliferative and cell protective properties.
  • the peptides according to the invention can have disulfide bridges, so that they have the general formula
  • the peptides have a glycine at one or more of the following positions in the amino acid sequence.
  • X ] at position 8 is L or V and / or X, at position 11 is L or I and / or X 2 at position 1 D or.
  • N is and / or X 2 at position 9 is K or R and / or X 3 at position 3 is S or A and / or at position 8 is R or A.
  • R is selected from
  • APSEEDHSILWDAISTYDGSKALHVTNIKKWKEP SEQ ID NO: 1
  • GGKHHLGLEEPKKLRPPPARTP SEQ ID NO: 2
  • GKGGKHHLGLEEPKKLRPPPARTP SEQ ID NO: 3
  • NKNGFYHSR SEQ ID NO 14
  • DHRGFYRKR (SEQ ID NO 19) and / or
  • RSSQGQRRGP (SEQ ID NO 25) and / or
  • YP NGKRIPGSPEIRGDPN (SEQ ID NO 26), NPNTGKLIQGAPTIRGDPE (SEQ ID NO 27), DKYGQPLPGYTTKGKEDVH (SEQ ID NO 28), DRKTGVKLPGGLEPKGELD (SEQ ID NO 29), DKYYGMGGGLGQD and or
  • R 2 selected from
  • Preferred peptides have the following sequences IGFBP-1
  • the peptides according to the invention can be obtained by purification from human blood filtrate or urine, by solid phase peptide synthesis or by expression in recombinant microorganisms.
  • the invention furthermore relates to the complexes of the peptides according to the invention with human insulin-like growth factor-I and / or human insulin-like growth factor-II and their physiologically active fragments and / or derivatives, in particular amidated, acetylated, sulfated, phosphorylated and / or glycosylated derivatives.
  • the invention furthermore relates to nucleic acids which code for the peptides according to the invention, antisense nucleotides which bind under stringent conditions to a nucleic acid which codes for the peptide according to the invention, antibodies which bind to the peptides according to the invention, inhibitors which inhibit the biological activity of the insulin -like growth factor binding proteins, inhibitors that inhibit the expression of insulin-like growth factor binding proteins.
  • the peptides, complexes, nucleic acids, antisense nucleotides, antibodies and inhibitors according to the invention are particularly suitable for the manufacture of a medicament for the treatment of over- or under-expression of insulin-like growth factor binding proteins, for the treatment of muscle loss, osteoporosis, diabetes, amyloidal lateral sclerosis, peripheral - Central and central neuropathies, inflammatory processes, disturbed inflammatory reactions, tumor disorders, inflammatory and neoplastic diseases, growth disorders, musculoskeletal disorders, diseases of the bone apparatus and / or for wound and bone healing.
  • IGFBP IGF-I or IGF-II are particularly suitable for the treatment of bone diseases.
  • the peptides according to the invention and the complexes of the peptides with insulin-like growth factor have a cell proliferative activity.
  • the peptides according to the invention regulate the release of IGF-I and IGF-II from the complexes at their site of action.
  • the co-administration of the peptides according to the invention with IGF-I or IGF-II extends the biological half-life and thus the availability of the latter.
  • the hypoglycemia induced by injection of free IGF-I or IGF-II is prevented by the co-administration of the peptides according to the invention.
  • the peptides according to the invention furthermore have a growth-promoting effect on bone cells and lead to an enhancement or modulation of the action of growth hormones.
  • the peptides, complexes, nucleic acids, antisense nucleotides, antibodies and inhibitors according to the invention are contained in a pharmaceutical in a pharmaceutical dosage form. They are suitable for oral, intravenous, intramuscular, intracutaneous, intrathecal use or as an aerosol for transpulmonary application.
  • the amount of peptide to be administered is 1 ⁇ g to 1 g per administration unit per day.
  • nucleic acids and / or antisense nucleotides according to the invention are also suitable for the manufacture of a medicament for the treatment of somatic or non-somatic genetic diseases.
  • the diagnostic agent according to the invention contains the peptides, complexes, nucleic acids, antisense nucleotides, antibodies and / or inhibitors according to the invention.
  • the diagnostic agent preferably contains poly- or monoclonal antibodies to the peptide according to the invention, it being possible for the antibodies to be labeled with fluorescence or radioactive in order to be able to be used in the known ELISA or RIA.
  • the diagnostic agent can also contain nucleic acids, which are used in modified or labeled form in tests known to those skilled in the art, such as PCR or finger printing.
  • the diagnostic agents according to the invention are particularly suitable for the diagnosis of functional disorders of the bones, the muscles, the nervous system, the lymph organs, the gastric Intestinal tract, immune system, diabetes, inflammatory and neoplastic processes as well as a marker for cancer.
  • the simultaneous appearance of several fragments of BP-4 or BP-5 in the plasma, in particular the N- and C-termmal domains, is suitable as a marker for diseases of the bone metabolism.
  • the corresponding peptides can either be detected by mass spectroscopy or, preferably by an immune reaction with the corresponding antibodies.
  • FIG. 1 shows an alignment of the consensus sequences of C-terminal fragments of the insulin-like growth factor proteins.
  • FIG. 2 shows the schematic structure of the insulin-like growth factor proteins with the cysteine-rich N- and C-terminal domains.
  • FIG. 3 shows the schematic structure of the insulin-like growth factor proteins and the sequence of the biologically active fragments isolated from hemofiltrate.
  • FIG. 4 shows the isolation of the osteoanabolic factor IGFBP-4-11 from human hemofiltrate (see example 3).
  • Figure 5 shows the sequence and sulfur bridge analysis of the osteoanabolic factor IGFBP-4- 11.
  • the cysteines 153-183, 194-205 and 207-228 are bridged.
  • Figure 6 shows the biological effect of the osteoanabolic factor IGFBP-4-11. After incubation of serum-free primary rat osteoblasts for (A) 24 hours, (B) 48 hours and (C) 72 hours with IGFBP-4-11, the proliferation-promoting effect of IGFBP-4-11 can be seen. An increase in the rate of DNA synthesis is found in a dose-dependent manner, measured as the incorporation of bromodeoxyuridine (BrdU).
  • Figure 7 shows the specific binding to osteoblasts and the possible receptor for the osteoanabolic factor IGFBP-4-11 (designated as IGFBP-4 136 "237 ).
  • A Radioactively labeled IGFBP-4-11 shows an unlabelled by increasing amounts IGFBP-4-11 displaceable specific binding to primary osteoblast cells
  • B Radioactively labeled IGFBP-4-11 could, after binding to osteoblasts, be chemically cross-linked with its putative receptor molecule and then by gel electrophoresis and subsequent authorization. diography can be demonstrated.
  • the ligand-receptor complex has a molecular weight of approximately 120 kDa. The formation of the complex is promoted by saponin, a membrane pore former. The complex formation is prevented by adding an excess of unlabelled IGFBP-4-11 to the incubation batch.
  • the peptides according to the invention can be obtained from a human hemofiltrate by a purification process.
  • This patented process (Forssmann, W.-G. (1988), publication DE 36 33 707 AI), which was developed for the extraction of proteins from hemofiltrate, was also used in a modified form to purify the peptide complex.
  • H. hemofiltrate accumulates in large quantities in the ultrafiltration of the blood of kidney patients. 800 to 1,000 1 hemofiltrate are adjusted to a pH of 2.1 with HCl and diluted with water to a conductivity of 5.5 mS / cm and applied to a strong cation exchanger at a flow rate of 3 1 / min.
  • Buffer A Hemofiltrate pH 2.1, conductivity 5.5 mS / cm
  • Buffer B 0.5 M ammonium acetate
  • ammonium acetate eluates of the batch extraction are combined in amounts of 5,000 to 10,000 1 hemofiltrate peptide.
  • the peptide extract is applied to the preparative cation exchanger with the addition of demineralized water with a conductivity of 5.5 mS / cm.
  • the column is rinsed with 0.01 M HCl until the conductivity is below 1 mS / cm.
  • the elution is carried out in several stages using the buffers specified below
  • Eluates 1-7 are referred to as pH pool I-VII. They are collected separately and then rinsed with demineralized water. The elution takes place until a new baseline is reached. never, with elution volumes of 10 to 25 1 being achieved for the individual pH pools I to VII.
  • the individual pH pools are separated for fractionation and simultaneous desalination using a reverse phase chromatography
  • Pillar FineLine 100 (Pharmacia, Freiburg)
  • Buffer B 80% acetonitrile in 10 mM HCl
  • the column is rinsed with buffer A. Fractions of 200 ml are collected during the elution. Aliquots of the fractions are tested in the bioassay. The fractions are freeze-dried and stored at -20EC.
  • the bioactive fractions 11 and 12 from pH pool V in the assay were separated using a semi-preparative reverse-phase column. Fractions 21 to 25 contained the substance according to the invention.
  • Buffer B 0.1% TFA, 80% acetonitrile
  • Buffer A 0.1% TFA, 20% methanol
  • Buffer B 0.1% TFA, 100% methanol
  • Buffer A 20 mM sodium phosphate, pH 3.0
  • Buffer B 20 mM sodium phosphate, pH 3.0, 1.5 M NaCl
  • Fraction 56 contained the substance according to the invention.
  • Buffer B 0.1% TFA, 80% acetonitrile
  • the bioactive fraction 56 from the previous separation step was further purified on an analytical reverse phase column.
  • Filling material YMC RP-C18, 5 ⁇ m, 300 ⁇
  • Buffer B 0.1% TFA, 80% acetonitrile
  • bioactive fraction 45 from the previous separation step was subjected directly to the mass and sequence analysis. Another portion was reduced and alkylated (as described in Example 2) and then further purified on an analytical reverse phase column.
  • Filling material Zorbax RP-C3, 5 ⁇ m, 300 ⁇ analytics is used, clearly.
  • IGF-II 7471 Da; IGFBP-2, 12,681 Da; IGFBP-2, 12 865 Da
  • Cysteines can be detected in peptide sequencing after prior chemical derivatization, for example after reduction with ß-mercaptoethanol and carboxamidomethylation with iodoacetamide. After derivatization, desalting is preferably followed by analytical reverse phase chromatography with a Vydac RP-C18 column (4.6 mm x 25 cm). Some of the peptides modified in this way are fed to the sequence analysis, with the other part the mass determinations give a corresponding molecular weight. From the mass difference to the native peptide, it is concluded that the peptides from hemofiltrate contain six cysteines, which are also connected to one another with three disulfide bridges.
  • IGFBP-2-13 MW 12681
  • IGFBP-2-13 MW 12865
  • the peptide sequences are 100% identical to the amino acids of human IGFBP-2 derived from the cDNA or to the amino acid sequence of IGF-II.
  • IGFBP-2 has so far been described as a 34 kD binding protein, the complete sequence analysis of which was carried out by analysis of the associated cDNA (Binkert, C. et al., EMBO Journal Vol. 8 (1989), pages 2497 to 2502).
  • IGF-II and IGF-I which also binds to IGFBP-2, have been extensively described in their structure at the protein and DNA sequence level (as a review: Rechler, MM, & Nissley, SP (1990) insulin-like growth factors In: Peptide growth factors and their receptors (Spori, MB, Roberts, AB eds.), pages 263 to 367, Springer-Verlag, Berlin).
  • the IGF / IGFBP-2-13 was isolated on the basis of its biological activity in a survival assay of the PC-12 (pheochromocytoma cells) cell line. For this purpose, aliquots of the individual chromatography steps described in Example 1 were freeze-dried and then fed to the biological assay. The fractions, which each gave a positive signal, were subjected to further purification.
  • the assay measures cell survival after being serum-free by determining mitochondrial enzyme activity 24 hours after serum deprivation.
  • Nerve growth factor (NGF) or fetal calf serum (FCS) is used as a positive control in this assay.
  • 10,000 PC-12 cells per hole are sown in 96-well plates in serum-free medium. Aliquots (approx. 100 ml equivalent of the starting material) are added to the wells. 20 hours later, the survival rate of the cells is measured using a Wst-1 substrate. This substrate is converted by mitochondrial enzymes. The resulting dye intensity is measured at 405 nm in an ELISA reader, the reference wavelength is over 600 nm.
  • the IGF / IGFBP-2-13 complex has a dose-dependent, survival-promoting effect on PC-12 cells. These cells correspond to neuronal progenitor cells, so that it can be assumed that IGF / IGFBP-2-13 is a neuroprotective factor.
  • the bioactive fraction 33 from pH pool IV in the assay was separated on an analytical reverse phase column. Fraction 34 contained the substance according to the invention.
  • Buffer B 0.1% TFA, 80% acetonitrile
  • Mass determinations The mass determinations were carried out on an electrospray mass spectrometer. The molecular weight of the peptide was as
  • the C-terminus was determined by comparing the measured molecular mass with the mass calculated from the sequence. The agreement of these masses lies in the measuring accuracy of the electrospray mass spectrometer of 0.1% of the total mass.
  • the peptide sequence is 100% identical to the amino acids of human IGFBP-4 derived from the cDNA.
  • the sulfur bridge linkage was analyzed by cleaving the native peptide IGFBP-4-11 in parallel in two different batches with the endoproteases chymotrypsin and Arg-C. The cleavage fragments obtained were then separated from one another by means of analytical reverse phase chromatography and subjected to the molecular mass and sequence analysis. The following fragments, each containing two cysteines and a sulfur bridge, were obtained: HPKQCHPALDGQRGKCW, MW 1960
  • the IGFBP-4-11 was isolated on the basis of its biological activity in a proliferation assay with primary bone cells (osteoblasts), which are initially isolated from the skullcap of rat embryos
  • TGF-beta Transforming growth factor-beta
  • FCS fetal calf serum
  • the proliferation rate (DNA synthesis rate) of the cells is measured by adding and incorporating radioactive thymidine.
  • the peptide IGFBP-4-11 has a proliferation-promoting effect on these primary osteoblasts. These cells correspond to typical bone cells, so it can be assumed that IGFBP-4-11 is an osteoanabolic factor.
  • the theoretical mass is 12.5 kD, so it can be assumed that the peptide is glycosylated on serine or theronine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides qui se caractérisent en ce que leur séquence d'aminoacide correspond à des parties de la séquence d'aminoacide de la protéine liant le facteur de croissance de substances apparentées à l'insuline. L'invention concerne en outre des dérivés cycliques, glycosylés, phosphorylés, acétylés, amidés et/ou sulfatés.
EP98965865A 1997-12-22 1998-12-22 Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation Withdrawn EP1042476A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19757250 1997-12-22
DE19757250A DE19757250A1 (de) 1997-12-22 1997-12-22 Insulin-like growth factor binding protein und seine Verwendung
PCT/EP1998/008405 WO1999032620A1 (fr) 1997-12-22 1998-12-22 Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation

Publications (1)

Publication Number Publication Date
EP1042476A1 true EP1042476A1 (fr) 2000-10-11

Family

ID=7853008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98965865A Withdrawn EP1042476A1 (fr) 1997-12-22 1998-12-22 Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation

Country Status (5)

Country Link
EP (1) EP1042476A1 (fr)
JP (1) JP2002508931A (fr)
CA (1) CA2315974A1 (fr)
DE (1) DE19757250A1 (fr)
WO (1) WO1999032620A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
WO2000040612A1 (fr) 1999-01-06 2000-07-13 Genentech, Inc. Variants mutants du facteur de croissance i semblable a l'insuline (igf)
US7115382B1 (en) 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
EP1169058B1 (fr) * 1999-03-15 2007-05-09 Mayo Foundation For Medical Education And Research Facteur de croissance similaire a l'insuline et liant la protease de proteine 4
CN1320629A (zh) * 2000-04-27 2001-11-07 上海博德基因开发有限公司 一种新的多肽——人胰岛素样生长因子结合蛋白9和编码这种多肽的多核苷酸
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
CN1328055A (zh) * 2000-06-14 2001-12-26 上海博德基因开发有限公司 一种新的多肽——胰岛素类似生长因子结合蛋白16.17和编码这种多肽的多核苷酸
CN1328049A (zh) * 2000-06-14 2001-12-26 上海博德基因开发有限公司 一种新的多肽——胰岛素类似生长因子结合蛋白11.88和编码这种多肽的多核苷酸
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
CA2449290A1 (fr) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
WO2004043395A2 (fr) * 2002-11-14 2004-05-27 Wyeth Methodes et compositions permettant de traiter des troubles neurologiques
WO2005033132A2 (fr) 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
ES2341295T3 (es) * 2005-09-05 2010-06-17 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
GB0521276D0 (en) * 2005-10-19 2005-11-30 Lewitt Moira S Medical uses and therapies based upon the action of azurocidin on IGFBP-1
JP5260303B2 (ja) * 2005-11-30 2013-08-14 ネステク ソシエテ アノニム 筋肉損失の治療のための方法
WO2008086813A2 (fr) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides dérivés de protéines de la superfamille de l'insuline
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010141811A2 (fr) * 2009-06-04 2010-12-09 The University Of North Carolina At Chapel Hill Composés et procédés pour traiter des troubles osseux et réguler le poids
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
KR101482708B1 (ko) * 2012-10-09 2015-01-14 성균관대학교산학협력단 헤파린 결합 도메인을 포함하는 ｉｇｆｂｐ-5의 ｃ-말단 도메인의 신생 혈관 생성 억제제로서의 신규한 용도
US20160039897A1 (en) * 2013-03-12 2016-02-11 The University Of North Carolina At Chapel Hill Compounds and methods for treating obesity and controlling weight
JP2021525261A (ja) * 2018-05-24 2021-09-24 アモライト・ファルマ 代謝疾患の治療におけるｉｇｆｂｐ−２のヘパリン結合ドメイン
US20220259265A1 (en) * 2019-07-30 2022-08-18 The University Of Sydney Inhibitors and Use Thereof in Cancer Treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556344B1 (fr) * 1991-01-08 2003-08-13 Chiron Corporation Nouvelle proteine de fixation du facteur de croissance proche de l'insuline
CA2148685A1 (fr) * 1992-11-04 1994-05-11 Dennis L. Andress Proteines tronquees se liant a un facteur de croissance apparente a l'insuline, et possedant une activite mitogene
CA2169953A1 (fr) * 1994-06-27 1996-01-04 Masaaki Goto Facteur de croissance ii (bogf-ii) de l'osteoblaste de base et procede pour le produire
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
CA2195474A1 (fr) * 1994-07-20 1996-02-01 Cedo Martin Bagi Complexe igf/igfbp pour promouvoir la formation de tissu osseux et pour reguler le remodelage osseux
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9932620A1 *

Also Published As

Publication number Publication date
WO1999032620A1 (fr) 1999-07-01
DE19757250A1 (de) 1999-07-01
JP2002508931A (ja) 2002-03-26
CA2315974A1 (fr) 1999-07-01
WO1999032620A9 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
EP1042476A1 (fr) Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation
EP1027440B2 (fr) Proteine inhibitrice de la voie de signalisation wnt
Yates et al. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents.
DE3852086T2 (de) Therapeutische Peptide.
DE69602756T2 (de) Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
EP0167575B1 (fr) Cardiodilatine, une nouvelle hormone peptidique et son procede de fabrication
DE69132814T2 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
EP0892811B1 (fr) Peptide presentant des proprietes antiproliferatives
DE68929134T2 (de) Endothelin-DNA und Verwendung davon
DE102007030904A1 (de) Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
EP0885904A1 (fr) Peptides agonistes et/ou inhibiteurs de la formation d'amyloide et/ou de cytotoxicité et leur utilisation contre la maladie d'Alzheimer, le diabète sucré de type II et l'encéphalopathie spongiforme
DE69132813T2 (de) Genetisches igfbp-5 rodierendes material
EP0736095B1 (fr) Cytokine humaine circulante cc-1
DE69131979T2 (de) Genetisches igfbp-4 rodierendes material
DE68921665T2 (de) Hemmer vom flüssigen kalziumerhöhenden Faktor.
EP1959013B1 (fr) Peptide inhibiteur de virus humain (VIRIP) et son utilisation
DE68927854T2 (de) Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide
DE69121964T2 (de) Wachstumsinhibierender Faktor und für den wachstumsinhibierenden Faktor kodierender cDNS
EP1023445B1 (fr) Facteur de croissance derive de la cadherine et son utilisation
DE69737986T2 (de) Epimorphin antagonist und herstellungsverfahren dafür
WO1997020049A1 (fr) Peptide humain circulant dans le sang et possedant un effet insulinotrope
DE19951824A1 (de) Humanes zirkulierendes Insulin-like Growth Factor Binding Protein-3 Fragment und seine Verwendung
WO1997040073A2 (fr) PROTEINE BIOLOGIQUEMENT ACTIVE (FRAGMENT DE COLLAGENE HF-COLL-18/514cf) SERVANT A INHIBER LA CROISSANCE DE TUMEURS ET LES PROLIFERATIONS CAPILLAIRES
EP1056857A2 (fr) Transporteur pour medicaments a couplage saccharidique
DE69813232T2 (de) Wespe pompilid neuropeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IE IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040630